A federal judge has made it official: Abbott Laboratories owes the government $700 million in penalties for promoting its epilepsy drug Depakote for off-label use. The formal sentencing stems from the company's $1.6 billion settlement with the Department of Justice, which also included civil penalties.
Abbott Laboratories recently wrapped up its Depakote difficulties with the Department of Justice with a $1.6 billion off-label marketing settlement. Now, we discover that another Abbott ex-employee has blown the whistle, this time alleging that the company pushed its TriCor cholesterol remedy for off-label uses.
It's the second-largest off-label marketing settlement ever, topped only by Pfizer's $2.3 billion deal.
Abbott Laboratories ($ABT) has set aside $1.5 billion for a potential off-label marketing settlement with the U.S. Justice Department. Amid all the excitement about Abbott Laboratories' impending
The Abbott Laboratories epilepsy drug Depakote is the subject of another FDA safety announcement. This time, the agency is alerting that use by pregnant mothers increases the risk that their babies
Another off-label marketing settlement may be on its way. Abbott Laboratories is "engaged in active settlement discussions" with the Justice Department in a lawsuit claiming that the company
The Justice Department is joining a whistleblower suit against Abbott Laboratories that alleges the drugmaker promoted its seizure drug Depakote for off-label uses. Former employees claim Abbott
Federal prosecutors want to read Miles White's inbox. And a U.S. judge has ordered the Abbott Laboratories CEO to hand over some of his email messages as part of a federal investigation into whether
Abbott Laboratories gets a one-two safety punch today. First, the FDA issued a reminder warning about birth defects in babies born to pregnant women who take Depakote, the epilepsy drug that's also
Abbott Laboratories is the latest drugmaker to find itself in the feds' sights. Officials are probing Abbott's marketing of the epilepsy-and-mood drug Depakote, examining whether the company violated